Clinical Use of PanoMap for Glaucoma: Frequently Damaged Areas in Early Glaucoma
نویسندگان
چکیده
منابع مشابه
Stem Cells in Glaucoma Management
Glaucoma is the leading cause of preventable blindness worldwide. Despite tremendous advances in medical and surgical management of glaucoma in the recent years, the prevalence of glaucoma related blindness is anticipated to increase in the future decades because of the aging population. Stem cells have the potential to change the glaucoma management in several ways. There are several areas of ...
متن کاملUse of the structure-function relationship in detecting glaucoma progression in early glaucoma
BACKGROUND To evaluate the use of optical coherence tomography (OCT) retinal nerve fiber layer (RNFL) thickness and visual field (VF) measurements in detecting disease progression in patients with early glaucoma. METHODS Over a 3-year period, this study examined 60 eyes of 39 glaucoma patients whose total deviation in the superior or inferior hemifield was more than -6 dB. All eyes underwent ...
متن کاملEarly diagnosis of glaucoma
Over recent years strategies used to combat the disease have included screening programmes, information to the population, the identification of populations at risk and the distribution of information between the various links in the health chain, from the GP or family doctor through to hospital professionals, not forgetting, first and foremost, opticians and optometrists, who are in direct con...
متن کاملEarly detection of glaucoma.
Primary open-angle glaucoma (often loosely called "chronic glaucoma") is one of the main causes of preventable loss of sight in Britain1 2 and throughout the world. All too often it is diagnosed only when loss ofthe visual fields is advanced and the condition is resistant to treatment.3 Early detection is therefore of the highest importance, especially with recent evidence that appreciable neur...
متن کاملClinical use of Bevacizumab in treating refractory glaucoma
UNLABELLED Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administrat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Glaucoma
سال: 2020
ISSN: 1057-0829
DOI: 10.1097/ijg.0000000000001690